HDL and triglyceride as therapeutic targets

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Preventive Cardiology

Background:

• Plasma HDL-cholesterol (HDL-C) is inversely related to coronary artery disease (CAD).
• Hypertriglyceridemia is an independent risk factor for coronary heart disease (CHD).
• The role of triglycerides and HDL-C as therapeutic targets for cardiovascular risk reduction is under investigation.

Purpose of the Study:

• To discuss the potential of triglycerides and HDL-cholesterol as therapeutic targets for reducing cardiovascular risk.
• To review current evidence on managing lipid levels in relation to cardiovascular outcomes.

Main Methods:

• Review of epidemiological studies and clinical trial data.
• Analysis of the impact of statins and fibrates on lipid profiles and cardiovascular events.
• Examination of current clinical practice guidelines (ATP III) regarding lipid targets.

Main Results:

• Triglyceride measurements alone may not fully capture atherogenic lipoprotein profiles.
• Statins effectively reduce LDL-cholesterol and atherogenic remnant lipoprotein cholesterol.
• Studies suggest statins and fibrates can improve triglyceride and HDL-C levels, impacting CHD risk.
• Low HDL-C (<40 mg/dL) is a significant CHD risk factor, but specific HDL-C goals are not yet established.

Conclusions:

• Lowering LDL-cholesterol remains the primary therapeutic target for cardiovascular risk reduction.
• Achieving triglyceride levels below 150 mg/dL is a secondary therapeutic target.
• Clinical trial data are insufficient to recommend specific HDL-cholesterol goals, despite its established role as a risk factor.